Robert Dreicer, MD, explains how intensifying treatment through the combination of androgen-deprivation therapy and androgen receptor pathway inhibitors (eg, abiraterone acetate [Zytiga], enzalutamide [Xtandi], and apalutamide [Erleada]) has improved outcomes in patients with metastatic castration-sensitive prostate cancer. Dreicer is deputy director, UVA Cancer Center, director, Solid Tumor Oncology in the Division of Hematology/Oncology, and a professor of medicine and urology, University of Virginia Health System.
Study: Lower PCSM is seen with radical prostatectomy vs other modalities
November 14th 2023"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.
Comparing Leuprolide Formulations in Advanced Prostate Cancer
November 13th 2023In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.